Class / Patent application number | Description | Number of patent applications / Date published |
514329000 | Nitrogen attached directly to the piperidine ring by nonionic bonding | 44 |
20080227817 | New Salt I - The invention provides N-{2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methyl-propyl)oxy]-4-hydroxyphenyl}acetamide benzoate or a solvate thereof, pharmaceutical compositions containing the salt or solvate and use of the salt or solvate in therapy. | 09-18-2008 |
20080249132 | Piperidine Carboxyamide Derivate Suitable as Tachykinin Receptor Antagonist - The present invention relates to the compound of formula (I) | 10-09-2008 |
20080275087 | BIPHENYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS - Biphenylcarboxamide compounds of formula (I) | 11-06-2008 |
20080280951 | Salt Il - The invention provides N-{2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methyl-propyl)oxy]-4-hydroxyphenyl}acetamide furoate or a solvate thereof, pharmaceutical compositions containing the salt or solvate and use of the salt or solvate in therapy. | 11-13-2008 |
20090124663 | Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors - This invention relates to novel N-phenyl-piperidine derivatives useful as monoamine neurotransmitter re-uptake inhibitors. | 05-14-2009 |
20090176834 | Sublingual fentanyl spray - The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable salt thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations. | 07-09-2009 |
20090239910 | Benzenesulfonamide Compounds and Their Use - The invention relates to azetidinyl, pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula I and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R | 09-24-2009 |
20100022595 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels - The invention relates to piperidinyl and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R | 01-28-2010 |
20100069438 | ANESTHESIA INDUCTION AND MAINTENANCE DRUG - Disclosed herein is a combination drug designed for use by anesthesiologists for the purposes of inducing and/or maintaining general anesthesia and minimizing the stress response to pain that results from the noxious stimuli associated with surgical procedures. The present invention is suitable for use in general anesthesia to decrease the need for muscle relaxant administering and permit patients to drive themselves home after receiving the anesthetic. This invention includes a combination drug comprised of propofol (2,6-diisopropylphenol) and remifentanil (N-phenyl-N-(4-piperidinyl)amides) in which the preferred embodiment contains 2 mcg of remifentanil for each 1 mg of propofol. The combination drug invention may include a package as two drugs of proper proportions shipped and sold in a two compartment vial or syringe for mixing immediately prior to use. Alternatively, the invention may comprise a single drug prepared with proper preservatives in an aqueous solution. | 03-18-2010 |
20100093800 | APPARATUS, METHOD AND DRUG PRODUCTS FOR PROVIDING A CONSCIOUS PATIENT RELIEF FROM PAIN AND ANXIETY ASSOCIATED WITH MEDICAL OR SURGICAL PROCEDURES - Disclosed is drug delivery for facilitating medical and/or procedures that are performed without “general anesthesia,” which is also described in the specification as the state of patient “unconsciousness” resulting from a drug administered by an anesthetist or anesthesiologist. Mixtures of sedative and analgesic drugs are adapted for safe and effective administration by devices to provide and maintain drug infusions that do not push the patient into unconsciousness and/or general anesthesia. Drug delivery devices are also disclosed that include the use of stored parameters and/or values that correlate to drug mixture delivery during a procedure, and a patient health monitor to measure and send signals regarding a patient health condition to a processor. | 04-15-2010 |
20100144792 | NEURITE FORMATION PROMOTER - The invention provides an agent for promoting ocular tissue neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof, and an agent for promoting corneal neuritogenesis and retinal neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof. The corneal neuritogenesis promoter can be used for the improvement of corneal sensitivity, treatment of dry eye, or treatment of a corneal epithelial disorder. The retinal neuritogenesis promoter can be used for the improvement of a visual dysfunction. | 06-10-2010 |
20100152242 | Transdermal Electrotransport Delivery Device Including an Antimicrobial Compatible Reservoir Composition - A transdermal electrotransport drug delivery device having an anode, a cathode and a source of electrical power electrically connected to the anode and the cathode. At least one of the anode and the cathode includes an electrode and a reservoir comprised of a housing composed of a polymeric material and an aqueous medium in contact with the housing. The aqueous medium includes (i) a drug or an electrolyte salt or a mixture thereof, (ii) propylene glycol, and (iii) an antimicrobial agent in an amount sufficient to inhibit microbial growth in the aqueous medium. The propylene glycol prevents the antimicrobial agent from being adsorbed by other materials used in the construction of the delivery device. A process for preparing a transdermal electrotransport drug delivery device is also provided. | 06-17-2010 |
20100190829 | RENIN INHIBITORS - Described are compounds that bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof. | 07-29-2010 |
20100197735 | NOVEL PHENYLUREA INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel phenylurea compounds of formula (I): | 08-05-2010 |
20100227885 | Selective Serotonin 2A/2C Receptor Inverse Agonists as Therapeutics for Neurodegenerative Diseases - Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis. | 09-09-2010 |
20100227886 | Selective Serotonin 2A/2C Receptor Inverse Agonists as Therapeutics for Neurodegenerative Diseases - Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis. | 09-09-2010 |
20100286204 | COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE - There is provided a compound having Formula I | 11-11-2010 |
20110003855 | ANTIVIRAL COMPOUNDS FOR THE TREATMENT OF HCV INFECTION - Disclosed are compounds and methods of synthesis of Formula I for the development of antiviral drugs for the treatment of HCV infection. | 01-06-2011 |
20110098322 | PREPARATION OF NOVEL 1,3-SUBSTITUTED UREAS AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE - The present invention provides compounds that can inhibit the activity of soluble epoxide hydrolases. In particular, the present invention provides compounds of Formula I. | 04-28-2011 |
20110195996 | Transmucosal Treatment Methods in Patients With Mucositis - In accordance with the invention is an fentanyl-containing dosage form designed for transmucosal delivery which includes both an effervescent couple and a pH adjusting substance which can be administered to patients suffering from both pain and mucositis. Also provided is a method of treating pain in a patient having mild oral mucositis by administering a fentanyl-containing dosage form designed for transmucosal delivery. | 08-11-2011 |
20110281914 | FENTANYL COMPOSITION FOR NASAL ADMINISTRATION - The treatment of acute pain with a sufficient dosage by intranasal administration of fentanyl results in a time to onset of action comparable to intravenous administration and a significantly faster onset of action than nasal titration of fentanyl. The nasal administration of a sufficient amount of fentanyl to obtain pain relief has lower maximum plasma concentrations comparable to intravenous administration and results in lower rates of adverse events like respiratory depression, nausea and vomiting. Compositions for use in the method are also disclosed. | 11-17-2011 |
20120071511 | FENTANYL-CONTAINING ADHESIVE PREPARATION FOR EXTERNAL USE - Disclosed is a fentanyl-containing adhesive preparation for external use, wherein an adhesive layer is laminated on a supporting body. The adhesive layer contains SIS, a tackifier resin that is composed of a rosin resin and terpene resin, and a softener that is composed of a plybutene and a liquid paraffin. The adhesive layer also contains fentanyl as an active ingredient. The fentanyl-containing adhesive preparation for external use has excellent skin permeation of fentanyl and high preparation stability, without suffering from crystallization of fentanyl during storage. | 03-22-2012 |
20120208849 | METHODS FOR CONTROLLING PAIN IN CANINES USING A TRANSDERMAL SOLUTION OF FENTANYL - This invention provides methods of controlling pain in a canine comprising transdermally administering a composition comprising fentanyl, a penetration enhancer, and a volatile liquid, wherein the composition is a solution. The invention also provides a single unit dose of the composition. | 08-16-2012 |
20120252845 | COMPOSITION FOR SUSTAINED DRUG DELIVERY COMPRISING GEOPOLYMERIC BINDER - The present invention relates to a sustained release medical composition comprising an active pharmaceutical ingredient and a geopolymeric binder. Preferably the active pharmaceutical ingredient is combined with the geopolymeric binder during the formation of that binder. | 10-04-2012 |
20120252846 | BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING PAIN - Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant. | 10-04-2012 |
20120270902 | N-substituted benzene sulfonamides - The invention provides N-substituted benzenesulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. | 10-25-2012 |
20120270903 | INTRANASAL SPRAY DEVICE CONTAINING PHARMACEUTICAL COMPOSITION - An intranasnal spray device contains a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (C | 10-25-2012 |
20120277267 | METHOD OF MANAGING OR TREATING PAIN - A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (C | 11-01-2012 |
20120322828 | METHODS FOR CONTROLLING PAIN IN EQUINES USING A TRANSDERMAL SOLUTION OF FENTANYL - This invention provides methods of controlling pain in an equine for an effective period of time comprising transdermally administering a composition comprising fentanyl, a penetration enhancer, and a volatile liquid, wherein the composition is a solution. The invention also provides a single unit dose of the composition. | 12-20-2012 |
20130137727 | SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES - Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis. | 05-30-2013 |
20130143925 | ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE - Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases. | 06-06-2013 |
20130143926 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS - The invention provides a compound which is (a) a phenylamide derivative of formula (I) or a tautomer thereof, or (b) a pharmaceutically acceptable salt, N-oxide, hydrate, prodrug or solvate thereof: wherein R | 06-06-2013 |
20130296368 | SUBLINGUAL FENTANYL SPRAY - The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable sale thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations. | 11-07-2013 |
20140179740 | STABLE LIQUID REMIFENTANIL FORMULATIONS - A stable, non-aqueous, liquid pharmaceutical composition contains remifentanil dissolved in a non-aqueous solvent. The formulation is provided with a pH ranging from about 2.0 to about 3.5 and can be used as an injectable. A method for preparing the formulation is also provided. | 06-26-2014 |
20140187585 | 5-HT2B RECEPTOR ANTAGONISTS - The present invention relates to novel fluorinated piperidine derivatives having antagonistic activity at the 5-HT | 07-03-2014 |
20140343100 | SUBLINGUAL FENTANYL SPRAY - The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable salt thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations. | 11-20-2014 |
20150011586 | Acyl Piperidine Inhibitors of Soluble Epoxide Hydrolase - Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases. In some embodiments, the present invention provides a method for monitoring the activity of a soluble epoxide hydrolase, the method including contacting the soluble epoxide hydrolase with an amount of a compound of the present invention sufficient to produce a detectable change in the fluorescence of the soluble epoxide hydrolase by interacting with one or more tryptophan residues present in the catalytic site of said sEH. | 01-08-2015 |
20150057313 | MODULATING AFFERENT SIGNALS TO TREAT MEDICAL CONDITIONS - This document provides methods and materials for modulating afferent nerve signals to treat medical conditions such as CHF, CHF respiration, dyspnea, peripheral vascular disease (e.g., peripheral arterial disease or venous insufficiency), hypertension (e.g., age-associated hypertension, resistant hypertension, or chronic refractory hypertension), COPD, sleep apnea, and chronic forms of lung disease where muscle dysfunction is a part of the disease pathophysiology. For example, methods and materials involved in using electrical and/or chemical techniques to block or reduce afferent nerve signals (e.g., nerve signals of group III and/or IV afferents coming from skeletal muscle and/or the kidneys) are provided. | 02-26-2015 |
20150313888 | METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS USING PIMAVANSERN - Methods for the treatment of Parkinson's disease psychosis which comprise the administration of pimavanserin. | 11-05-2015 |
20160158161 | PLASTER CONTAINING FENTANYL - A process for producing an adhesive matrix for a transdermal therapeutic system comprising a cover layer, the adhesive matrix, and a removable protective layer. The process includes providing a solution comprising polybutyl titanate dissolved in heptane:ethyl alcohol, providing an acrylate copolymer consisting of units of 2-ethylhexyl acrylate, methacrylate and 2-hydroxyethyl acrylate, adding the solution to the acrylate copolymer to obtain a mixture, and adding fentanyl as an active ingredient to the mixture to obtain the adhesive matrix. | 06-09-2016 |
20160193142 | SUBLINGUAL FENTANYL SPRAY | 07-07-2016 |
20160193200 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | 07-07-2016 |
20160200683 | ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | 07-14-2016 |
20160250200 | SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES | 09-01-2016 |